• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants

tetano

Editor, Senior Moderator
Cell Rep


. 2022 Mar 7;110558.
doi: 10.1016/j.celrep.2022.110558. Online ahead of print.
Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants


Yali Zhang[SUP] 1 [/SUP], Min Wei[SUP] 1 [/SUP], Yangtao Wu[SUP] 1 [/SUP], Juan Wang[SUP] 1 [/SUP], Yuting Hong[SUP] 1 [/SUP], Yang Huang[SUP] 1 [/SUP], Lunzhi Yuan[SUP] 1 [/SUP], Jian Ma[SUP] 1 [/SUP], Kai Wang[SUP] 1 [/SUP], Shaojuan Wang[SUP] 1 [/SUP], Yang Shi[SUP] 1 [/SUP], Zikang Wang[SUP] 1 [/SUP], Huilin Guo[SUP] 1 [/SUP], Jin Xiao[SUP] 1 [/SUP], Chuanlai Yang[SUP] 1 [/SUP], Jianghui Ye[SUP] 1 [/SUP], Jijing Chen[SUP] 1 [/SUP], Yuxi Liu[SUP] 1 [/SUP], Baorong Fu[SUP] 1 [/SUP], Miaolin Lan[SUP] 1 [/SUP], Peixuan Gong[SUP] 1 [/SUP], Zehong Huang[SUP] 1 [/SUP], Yingying Su[SUP] 1 [/SUP], Yixin Chen[SUP] 1 [/SUP], Tianying Zhang[SUP] 1 [/SUP], Jun Zhang[SUP] 1 [/SUP], Huachen Zhu[SUP] 2 [/SUP], Hai Yu[SUP] 3 [/SUP], Quan Yuan[SUP] 4 [/SUP], Tong Cheng[SUP] 5 [/SUP], Yi Guan[SUP] 6 [/SUP], Ningshao Xia[SUP] 7 [/SUP]



Affiliations

Abstract

Mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) may alter viral host tropism and affect the activities of neutralizing antibodies. Here, we investigated 153 RBD mutants and 11 globally circulating variants of concern (VOCs) and variants of interest (VOIs) (including Omicron) for their antigenic changes and cross-species tropism in cells expressing 18 ACE2 orthologs. Several RBD mutations strengthened viral infectivity in cells expressing ACE2 orthologs of non-human animals, particularly those less susceptible to the ancestral strain. The mutations surrounding amino acids (aas) 439-448 and aa 484 are more likely to cause neutralization resistance. Strikingly, enhanced cross-species infection potential in the mouse and ferret, instead of the neutralization-escape scores of the mutations, account for the positive correlation with the cumulative prevalence of mutations in humans. These findings present insights for potential drivers of circulating SARS-CoV-2 variants and provide informative parameters for tracking and forecasting spreading mutations.

Keywords: ACE2 receptor; CP: Immunology; CP: Microbiology; RBD mutations; SARS-CoV-2 variants; cross-species tropism; neutralization resistance; variants of concern; variants of interest.
 
Back
Top Bottom